IASO Bio Overview

  • Founded
  • 2017
  • Status
  • Private
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $60M
Latest Deal Amount
  • Investors
  • 1

IASO Bio General Information


Developer of cancer biotherapeutics. The company's cell-therapy products aim to treat symptoms of hematological tumors, solid tumors and virus associated tumors, enabling healthcare providers to prescribe more effective treatments to their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 9-10th Floor, Block D, Zhongdan Park
  • No. 3-1 Xinjinhu Road, Jiangbei New District
  • Nanjing, Jiangsu
  • China
+86 025 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

IASO Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series B) 23-Mar-2020 $60M 0000 Completed Pre-Clinical Trials
To view IASO Bio’s complete valuation and funding history, request access »

IASO Bio Executive Team (1)

Name Title Board Seat Contact Info
Jinhua Zhang Chief Executive Officer & Founder
To view IASO Bio’s complete executive team members history, request access »

IASO Bio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Hillhouse Capital Group PE/Buyout Minority 000 0000 000000 0
To view IASO Bio’s complete investors history, request access »